ReviewBiosensors2025
Nano-Engineered Sensor Systems for Disease Diagnostics: Advances in Smart Healthcare Applications.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The role of nanoparticles in the treatment of diabetic foot ulcers: mechanisms, delivery platforms, translational challenges, and future directions.Discover nano · 2026Review
- Smart Nano-Antibiotics: AI-Guided Stimuli-Responsive Nanoplatforms for Precision Antimicrobial Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Smart nanomaterials enabling drug delivery and glucose monitoring for diabetes management.Discover nano · 2026Review
- Combating Drug-Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics.Pulmonary medicine · 2026Review
- Nanostructure driven innovation in diabetes: from enhanced biosensing to smart therapeutic delivery.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nano-engineered sensor systems represent a paradigm shift in disease diagnostics, offering unprecedented capabilities for precision medicine. This review methodically evaluates these advanced platforms, consolidating recent advancements across four critical clinical domains: diabetes monitoring, cancer detection, infectious disease diagnostics and cardiac/genetic health. We demonstrate how the unique properties of nanomaterials, such as graphene, quantum dots and plasmonic nanoparticles, are being harnessed to achieve remarkable gains in analytical sensitivity, selectivity and real-time monitoring. Specific breakthroughs include graphene-based sensors attaining clinically significant limits for continuous glucose monitoring, quantum dot bioconjugates enabling ultrasensitive imaging of cancer biomarkers and surface-enhanced Raman spectroscopy (SERS) probes facilitating early tumor identification. Furthermore, nanosensors exhibit exceptional precision in detecting viral antigens and genetic mutations, underscoring their robust translational potential. Collectively, these developments signal a clear trajectory toward integrated, intelligent healthcare ecosystems. However, for these promising technologies to transition into accessible and cost-effective diagnostic solutions, persistent challenges in scalability, manufacturing reproducibility and long-term biocompatibility must be addressed through continued interdisciplinary innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.